![Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty](https://oncodaily.com/pub/uploads/2023/07/F095HDcXgAArv_A-1280x704.jpeg)
Photo taken from: Debyani Chakravarty / Twitter
Jul 17, 2023, 09:59
Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty
My OncoKB people: Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC.
Looking fwd to it getting tumor agnostic approval based on Alison Schram work showing 42% ORR in PDAC (& 35% in NSCLC).
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 1, 2024, 17:00